Fezolinetant associated with reduced hot flash frequency vs. other nonhormone therapies

Fezolinetant 45 mg once daily was statistically significantly more effective in reducing moderate to severe vasomotor symptom frequency compared with other nonhormonal — but not hormone-based — therapies in the U.S., researchers reported.
Fezolinetant (Veozah, Astellas) is a nonhormone neurokinin 3 receptor antagonist that was FDA approved in May for treatment of moderate to severe vasomotor symptoms due to menopause.
“In two phase 3 randomized, double-blind trials, SKYLIGHT-1 and SKYLIGHT-2, fezolinetant 45 mg daily significantly reduced the frequency and severity of moderate

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.